Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 10, 2001, Pages 552-560

  Stuart, Monic J ^a   Chao, Nelson S ^a   Horning, Sandra J ^a   Wong, Ruby M ^a   Negrin, Robert S ^a   Johnston, Laura J ^a   Shizuru, Judith A ^a   Long, Gwynn D ^a   Blume, Karl G ^a   Stockerl Goldstein, Keith E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CCNU; Hematopoietic cell transplantation; High dose chemotherapy; Hodgkin's disease

Indexed keywords

CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CBV PROTOCOL;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLADDER DYSFUNCTION; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOCRINE DISEASE; EYE TOXICITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFECTION; INFUSION SYSTEM; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; RESPIRATORY FAILURE; SCHOOL CHILD; SENSORY DYSFUNCTION; SKIN TOXICITY; STANDARD; SURVIVAL RATE; CHILD; COMPARATIVE STUDY; IATROGENIC DISEASE; INTERSTITIAL LUNG DISEASE; MAXIMUM TOLERATED DOSE; METHODOLOGY; MORTALITY; NONHODGKIN LYMPHOMA; PHARMACOKINETICS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHILD; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMAN; LOMUSTINE; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THERAPEUTIC EQUIVALENCY; TRANSPLANTATION, AUTOLOGOUS;

EID: 0035192938     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(01)70015-8     Document Type: Article

References (71)

1. Hodgkin's disease
2. Is there an effective salvage therapy for advanced Hodgkin's disease?
3. Salvage therapy of advanced Hodgkin's disease: Critical appraisal of curative potential
4. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure
5. Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy
6. Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease
7. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
8. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study: Societe Francaise de Greffe de Moelle
9. Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients
10. Autologous bone marrow transplantation for Hodgkin's disease
11. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients
12. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation
13. Nine year's experience with ABMT in 128 patients with Hodgkin's disease: An Italian study group report
14. Autologous bone marrow transplantation in Hodgkin's disease
15. High-dose therapy for Hodgkin's disease
16. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission
17. Intensive therapy and autotransplantation in Hodgkin's disease
18. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in with analysis of prognostic factors
19. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
20. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation
21. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
22. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy
23. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies
24. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
25. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors
26. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease
27. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center eight-year study of 155 patients
28. BEAM + autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single center: Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment
29. BEAM autografting in lymphoma: Experience at one centre
30. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas
31. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study
32. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy
33. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: A dose-finding study
34. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell Hodgkin's disease
35. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease
36. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU)
37. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: An assessment of risk factors
38. Pulmonary toxicity of carmustine in patients treated for malignant glioma
39. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study
40. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease: PMH Lymphoma Group, and the Toronto Autologous BMT Group
41. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study
42. Nitrosourea-associated pulmonary fibrosis
43. Toxicity of nitrosoureas
44. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma
45. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft
46. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia
47. Autologous blood stem cell transplantation
48. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells
49. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy
50. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma
51. Non-parametric estimation from incomplete observation
52. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: An assessment of risk factors
53. Idiopathic interstitial pneumonia following bone marrow transplantation: The relationship with total body irradiation
54. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis
55. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
56. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
57. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies
58. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site
59. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease
60. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients
61. Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia
62. Enhanced acute lung damage in mice following administration of 1,3- bis(2-chloroethyl)-1-nitrosourea
63. Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: Possible implications for lung toxicity
64. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation
65. The effects of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) and CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) on glutathione reductase and other enzymes in mouse tissue
66. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes
67. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease
68. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission chemotherapy
69. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
70. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
71. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood